WINT News and Press, Windtree Therapeutics Inc. From 05/16/22

WARRINGTON, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced management will host a conference call and webcast...

Windtree TherapeuticS press release (NASDAQ:WINT): Q1 GAAP EPS of -$0.29 beats by $0.01. Cash and cash equivalents of $15.5M is sufficient to provide runway into the first quarter of 2023. For further details see: Windtree TherapeuticS GAAP EPS of -$0.29 beats by $0.01

Announced positive topline results from Phase 2 SEISMiC study of istaroxime in early cardiogenic shock Late-breaker presentation of additional SEISMiC study results at the European Society of Cardiology (ESC) Heart Failure Conference. Management to host investor ...

Gainers: Cyngn (CYN) +70%. Sky Harbour Group (SKYH) +28%. Redbox Entertainment (RDBX) +25%. Wrap Technologies (WRAP) +18%. Inozyme Pharma (INZY) +16%. MedAvail Holdings (MDVL) +14%. Red Cat Holdings (OTCQB:RCAT) +13%. Pulse Biosciences (PLSE) +12%. United Airlines Holdings (UAL) +11%. Alpha T...

Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...

WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced a late-breaker presentation at the upcoming Euro...

Understanding Penny Stocks And 3 Hot Ones to Watch Now Trading penny stocks can have a lot of intricacies that inexperienced investors don’t understand. However, if you take the time to learn about this type of trading, it can be a very lucrative investment. With penny stocks ...

Windtree Therapeutics (NASDAQ:WINT) has added ~33% in the pre-market Wednesday after the clinical-stage biotech reported topline data from its SEISMiC Phase 2 study for istaroxime in early cardiogenic shock. According to the company, the 60-patient global trial met the primary endpo...

WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced positive primary results with istaroxime in rapi...

WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer...